子宫内膜异位症患者腹腔液中血管内皮生长因子及其可溶性受体的测定被引量：11

Free vascular endothelial growth factor and its soluble receptor in peritoneal fluid from endometriosis patients

下载PDF

导出

摘要目的探讨子宫内膜异位症患者血管内皮生长因子可溶性受体1（soluble receptor 1 of vascular endothelial growth factor,s-VEGFR-1/soluble fms-like tyrosine kinase,SFlt-1）调节血管内皮生长因子（vascular endothelial growth factor,VEGF）活动的机制。方法采用酶联免疫吸附法（ELISA）,对28例子宫内膜异位症患者的腹腔液中游离的VEGF及s-VEGFR-1进行测定并计算活性指数（VEGF/s-VEGFR-1）。以10例正常生育期妇女为对照。结果①子宫内膜异位症组VEGF水平明显高于对照组（P〈0.01）。Ⅲ-Ⅳ期高于Ⅰ-Ⅱ期（P〈0.05）。②子宫内膜异位症组s-VEGFR-1水平也明显高于对照组（P〈0.01）。Ⅰ-Ⅱ期与Ⅲ-Ⅳ期之间无显著差异（P〉0.05）。③对照组、Ⅰ-Ⅱ期和Ⅲ-Ⅳ期VEGF活性指数分别为0.310、0.276和0.273。④子宫内膜异位症组增生期VEGF及s-VEGFR-1水平均明显高于分泌期（P〈0.01）。⑤子宫内膜异位症组增生期VEGF活性指数低于分泌期。结论VEGF在子宫内膜异位症的血管发生中有重要作用,但采用VEGF活性指数能更好地了解VEGF在病理学方面的作用。s-VEGFR-1对VEGF有下调作用。 Objective To better understand the regulation of the soluble receptor of vascular endothelial growth factor （VEGF）, s-VEGFR-1 （or soluble fms-like tyrosine kinase, SFh-1 ）, in angiogenetic process in endometriosis. Methods Levels of free VEGF and s-VEGFR-1 were measured by enzyme-linked immunosorbent assay （ELISA） in peritoneal fluid from 28 subjects with surgically confirmed endometriosis, and 10 controis with no clinical evidence of the disease and other diseases. Meanwhile, we calculated a VEGF activity index by means of the ratio VEGF/s-VEGFR-1. Results We found higher VEGF concentration in endometriotic lesions than controls （P 〈0. 01 ） and VEGF concentration in stage Ⅲ-Ⅳ was higher than in stage Ⅰ - Ⅱ（P 〈 0. 05 ）. S-VEGFR-1 concentration followed a similar pattern with VEGF （P 〈 0. 01 ）, but no statistically significant difference was found between stage Ⅲ-Ⅳ and stage Ⅰ-Ⅱ（P 〉 0.05）. VEGF activity index in controls, stage Ⅰ-Ⅱand stages Ⅲ-Ⅳ of endometriosis was 0.310, 0. 276 and 0.273, respectively. VEGF and s-VEGFR-1 concentration were also higher in proliferative phase than in secretory phase in endometriotic lesions （P 〈 0. 01 ）. VEGF activity index in proliferative phase was lower than in secretory phase of endometriosis. Conclusion VEGF certainly plays an important role in endometriosis and its progression. However, the activity index may be better to investigate the real role of VEGF in the pathology, s-VEGFR-1 can down-regulate VEGF activity.

作者史淑红李佃贵马秀菊

机构地区河北医科大学第二医院妇产科河北省中医院内科

出处《第三军医大学学报》 CAS CSCD 北大核心 2007年第10期976-978,共3页 Journal of Third Military Medical University

关键词子宫内膜异位症血管内皮生长因子血管内皮生长因子可溶性受体 endometriosis vascular endothelial growth factor soluble form of VEGFR-1 （s-VEGFR-1/ sFlt-1 ）

分类号 R392.11 [医药卫生—免疫学] R446.19 [医药卫生—诊断学]

引文网络
相关文献

参考文献7

1Helske S,Vuorela P,Carpen O,et al.Expression of vascular endothelial growth factor receptors 1,2 and 3 in placentas from normal and complicated pregnancies[J].Mol Hum Reprod,2001,7(2):205-210.
2Artini P G,Cristello F,Monti M,et al.Vascular endothelial growth factor and its soluble receptor in ovarian pathology[J].Gynecol Endocrinol,2005,21(1):50-56.
3余峰彬,杨映弘,龚明生,蔺宗义.肿瘤血管再生机理及抗血管再生疗法研究进展[J].中华外科杂志,2000,38(12):943-945. 被引量：7
4Wu L W,Mayo L D,Dunbar J D,et al.Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation[J].J Biol Chem,2000,275(7):5096-5103.
5Maynard S E,Min J Y,Merchan J,et al.Excess placental soluble fms-like tyrosine kinase 1 (sFlt 1) may contribute to endothelial dysfunction,hypertension,and proteinuria in preeclampsia[J].J Clin Invest,2003,111(5):649-558.
6Hornig C,Barleon B,Ahmad S,et al.Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids[J].Lab Invest,2000,80(4):443-454.
7Bae D G,Kim T D,Li G,et al.Anti-Flt1 peptide,a vascular endothelial growth factor receptor 1-specific hexapeptide,inhibits tumor growth and metastasis[J].Clin Cancer Res,2005,11(7):2651-2661.